| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8956272 | Cytotherapy | 2018 | 12 Pages |
Abstract
The process resulted in production of required cell doses for the first-in-human phase I NKG2D CAR T clinical trial and provides a robust, flexible base for further optimization of NKG2D CAR T-cell manufacturing.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Joana M. Murad, Susanne H. Baumeister, Lillian Werner, Heather Daley, Hélène Trébéden-Negre, Jake Reder, Charles L. Sentman, David Gilham, Frederic Lehmann, Sarah Snykers, Marie-Louise Sentman, Terri Wade, Adam Schmucker, Michael W. Fanger,